Bradley Hunter, MD
Medical Oncology · Salt Lake City, UTNPI 1235556382
Payments from drug & device makers
Across 363 payments — averaging $9047.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hoffmann-la Roche Limited$1.2M
- Roche Products Limited$494K
- Janssen Scientific Affairs, LLC$400K
- AbbVie$268K
- Genentech, Inc.$196K
- Bristol Myers Squibb$167K
- plus $587K from 18 others
Across 6 payments — averaging $2094.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$7K
- Novartis$6K
What the payments were for
- Consulting fees$100,01738%
- Speaking & faculty fees$133,54551%
- Travel & lodging$24,5809%
- Food & beverage$5,1322%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hoffmann-la Roche Limited | 14 | $1,172,548 |
| Roche Products Limited | 15 | $493,876 |
| Janssen Scientific Affairs, LLC | 9 | $399,678 |
| AbbVie | 52 | $267,872 |
| Genentech, Inc. | 12 | $195,672 |
| Bristol Myers Squibb | 14 | $167,227 |
| Gilead(2 entities) | 101 | $142,643 |
| Genmab A/s | 49 | $132,805 |
| Syndax Pharmaceuticals, Inc. | 12 | $110,967 |
| Sumitomo Pharma America, Inc. | 9 | $71,436 |
| Regeneron | 11 | $52,578 |
| Novartis | 24 | $27,926 |
| E.r. Squibb & Sons, L.L.C. | 14 | $21,388 |
| Genmab U.S., Inc. | 8 | $13,156 |
| Johnson & Johnson | 6 | $4,791 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $3,023 |
| Astellas Pharma Global Development | 1 | $2,500 |
| ADC Therapeutics America, Inc. | 1 | $2,000 |
| Janssen Global Services, LLC | 1 | $1,500 |
| Incyte Corporation | 2 | $237 |
| Telix Pharmaceuticals | 1 | $188 |
| Daiichi Sankyo Inc. | 1 | $151 |
| AstraZeneca | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,284,189 in reported general payments places this provider in the 85th percentile of 43 medical oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 12 | $111 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Salt Lake City
- Wallace AkerleySalt Lake City$12.7M
- Stephan KendallSalt Lake City$10.2M
- Ignacio Garrido-LagunaSalt Lake City$8.8M
- William McKeanSalt Lake City$3.4M
- Ahmad HalwaniSalt Lake City$2.3M
- Paul ShamiSalt Lake City$1.5M
- Kenneth GrossmannSalt Lake City$931K
- Martha GlennSalt Lake City$768K
- Jeff RussellSalt Lake City$739K
- Mei WeiSalt Lake City$304K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.